Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Am J Transplant. 2017 Jan 25;17(6):1574–1584. doi: 10.1111/ajt.14161

Figure 7. Allograft failure, eGFR decline, and AMR in patients with and without De novo DSA.

Figure 7

Graft failure, the composite end-point of graft failure and/or 50% reduction in GFR Acute, active AMR, and chronic AMR were higher in patients with dnDSA. Patients with both class I + II dnDSA had the highest rate of graft loss and 50% decline in eGFR. 94.4% (51/54) of patients received a biopsy. The mean follow-up post dn DSA was 3.2±2.0 years. * No patients with class I dnDSA only lost their allografts during follow-up. † All statistical comparisons were with the no dnDSA group.